In addition to the complete set of ACRIN 6657 imaging studies, curated data sets based on UCSF QC assessment, protocol compliance and data completeness are provided for download in the form of TCIA shared lists. These image data sets are accompanied by Excel files with patient clinical and outcome data.
Shared Lists: See descriptions below under "Curated Data Sets"
- Longest Diameter (LD) dataset -
- Good SER Functional Tumor Volume (FTV) dataset
- ACRIN 6657 Primary Aim Analysis dataset
Level 0: All I-SPY 1 / ACRIN 6657 Dataset
847 MR on-study studies (222 subjects) in UCSF image database.
One patient in the image data collection (I-SPY ID 1079 ) does not appear in the Feb. 2, 2011 I-SPY FINAL LOCKED clinical data set. So no clinical data is available.
- Patient 1079 does not appear in the Feb. 2, 2011 I-SPY FINAL LOCKED clinical data set. So no clinical data is available.
Reported in Hylton et al. (2012) *
This data is comprised of the patient studies analyzed and reported to ACRIN in 2008
, and used for the 2012 Radiology paper on ACRIN 6657 *. This data set is not provided as a shared list, as it is not recommended for use in any further analysis. It is described here because it is the data set from which the Level 3 (primary aim analysis) set was derived.
Level 2b consists of 707 MR studies (207 subjects) in the UCSF image database which were submitted to ACRIN at the close of the trial in 2008. Inclusion and exclusion was determined by quality and protocol reviews available at that time. In addition to the exclusion criteria listed for Level 2a, studies done with imaging in the axial plane, in violation of the sagittal orientation specified in the trial imaging protocol, were excluded due to processing limitations of the analysis software. Similarly, bi-lateral sagittal acquisitions (alternating left and right volumetric acquisitions) were excluded.
- Hylton NM, Blume JD, Bernreuter WK, et al: Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology 263:663-72, 2012
Specific inclusion/exclusion differences between Levels 2a and 2b:
14 studies rejected since 2008 (in Level 2b but not in 2a)
ID 1035, T4 *
ID 1055, T1 *
ID 1206, T1
* Subjects that were included in the primary aim analysis (Level 3)
Level 3: Subset of Level 2b used in primary aim analysis
586 MR studies (162 subjects) in UCSF image database
|45 subjects excluded from Level 2b set|
Case #: 128
Shared Lists For Curated Data Sets
The following links may be used to download the image series for To download image data sets for the curated data sets go to Tools / Search Shared Lists after logging in TCIA, and search for "ISPY1"
Shared lists have been created for each of the main curated data sets: Level 1, 2a, and 3. For each level one may download either:
"All Series" full MRI datasets including all original series and derived PE, SER maps and segmentation objects from the primary analysis
"DCE Only" Original DCE series only
Relative sizes of the lists and full collection are shown in the Table below. Estimated download times can be found by loading the shared list into the download manager from the Search Shared Lists tool. Links are also provided in the Table for Excel spreadsheet files containing selected patient clinical and outcome data for the patients in each set. Further data will be made available in the future as it is released by I-SPY. Outcome data may not be accessible by all users.
N / Size
DCE + Derived
N / Size
N DCE Only
N / Size
|Clinical data||Outcome data|
|Level 0: Complete image data set||222||7880 / 76GB||NA||NA|
|Level 1: Studies with MRI LD measurements||219||7778 / xxGB75GB||NA||NA|
|Level 2a: Studies with SER Volume measurements||208||6971 / 63GB||4022 / xxGB43GB||1243 / 24GB|
|Level 3: Studies used in primary aim analysis||162||5696 / 49GB|
3223 / 34GB
|961 / 18GB|
To download: Tools / Search Shared Lists
A data dictionary is provided. The dictionary includes descriptions of all private DICOM attributes used in the derived maps and segmentations generated by the volumetric analysis and QC evaluations. Also included are descriptions of ancillary data provided, including demographic, clinical and survival data.